Elagolix Sodium

噁拉戈利钠

Report date: 2026/02/10 20:00:22
NMEFirst In Class

Base Information

Drug NameElagolix Sodium
Drug Alias Name恶拉戈利Elagolix艾拉戈克钠Elagolixum艾拉戈利钠 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGonadotropin-releasing hormone receptor antagonists
TargetsGonadotropin-releasing hormone receptor
Therapy Area/IndicationsPainMenorrhagiaUterine Hemorrhage +[7] 
Global Approved IndicationsPainEndometriosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/07/23
Country/TerritoryCanadaUnited StatesPuerto Rico +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNeurocrine Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesWake Forest University Health SciencesYale UniversityColorado Center For Reproductive Medicine Llc +[4] 
Inactive CompaniesAbbott Laboratories
Active IndicationsPainMenorrhagiaEndometriosis +[5] 
Inactive IndicationsUterine HemorrhagePolycystic Ovary Syndrome

Other Information

ATC CodeH01CC03
Related LinksWikipediaDrugBankKEGG